CN1922332B - 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 - Google Patents

预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 Download PDF

Info

Publication number
CN1922332B
CN1922332B CN2004800421486A CN200480042148A CN1922332B CN 1922332 B CN1922332 B CN 1922332B CN 2004800421486 A CN2004800421486 A CN 2004800421486A CN 200480042148 A CN200480042148 A CN 200480042148A CN 1922332 B CN1922332 B CN 1922332B
Authority
CN
China
Prior art keywords
gene
cells
expression
cisplatin
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2004800421486A
Other languages
English (en)
Chinese (zh)
Other versions
CN1922332A (zh
Inventor
萨默·阿尔－穆拉尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penn State Research Foundation
Original Assignee
Penn State Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Research Foundation filed Critical Penn State Research Foundation
Publication of CN1922332A publication Critical patent/CN1922332A/zh
Application granted granted Critical
Publication of CN1922332B publication Critical patent/CN1922332B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2004800421486A 2003-12-31 2004-12-30 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 Expired - Fee Related CN1922332B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53350503P 2003-12-31 2003-12-31
US60/533,505 2003-12-31
PCT/US2004/043837 WO2005066371A2 (en) 2003-12-31 2004-12-30 Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201210472073.1A Division CN102989009B (zh) 2003-12-31 2004-12-30 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
CN201110195193.7A Division CN102321584B (zh) 2003-12-31 2004-12-30 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法

Publications (2)

Publication Number Publication Date
CN1922332A CN1922332A (zh) 2007-02-28
CN1922332B true CN1922332B (zh) 2013-06-12

Family

ID=34748910

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2004800421486A Expired - Fee Related CN1922332B (zh) 2003-12-31 2004-12-30 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
CN201110195193.7A Expired - Fee Related CN102321584B (zh) 2003-12-31 2004-12-30 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
CN201210472073.1A Expired - Fee Related CN102989009B (zh) 2003-12-31 2004-12-30 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201110195193.7A Expired - Fee Related CN102321584B (zh) 2003-12-31 2004-12-30 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
CN201210472073.1A Expired - Fee Related CN102989009B (zh) 2003-12-31 2004-12-30 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法

Country Status (7)

Country Link
US (5) US7700280B2 (enExample)
EP (2) EP2395112B1 (enExample)
JP (3) JP4682152B2 (enExample)
CN (3) CN1922332B (enExample)
ES (1) ES2394799T3 (enExample)
TW (1) TWI301066B (enExample)
WO (1) WO2005066371A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4682152B2 (ja) * 2003-12-31 2011-05-11 ザ・ペン・ステート・リサーチ・ファンデーション 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法
AU2006249235B2 (en) * 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US8420603B2 (en) * 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
EP3327031A1 (en) * 2004-05-14 2018-05-30 Abraxis BioScience, LLC Disease site-delivering pharmaceutical compositions comprising paclitaxel
US7553496B2 (en) * 2004-12-21 2009-06-30 University Of Kentucky Research Foundation VEGF-A as an inhibitor of angiogenesis and methods of using same
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2007072225A2 (en) * 2005-12-01 2007-06-28 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
ES2432759T3 (es) * 2006-06-13 2013-12-05 The Rockefeller University Nuevos métodos de diagnóstico
DE102006035393A1 (de) * 2006-11-02 2008-05-15 Signature Diagnostics Ag Prognostische Marker für die Klassifizierung des dreijährigen progessionsfreien Überlebens von Patienten mit Kolonkarzinomen basierend auf Expressionsprofilen von biologischen Proben
US20110178154A1 (en) * 2007-02-06 2011-07-21 Birrer Michael J gene expression profile that predicts ovarian cancer subject response to chemotherapy
WO2008109519A2 (en) * 2007-03-02 2008-09-12 University Of South Florida Micro-rna profiles associated with endometrial cancer development and response to cisplatin and doxorubicin chemotherapy
KR20100065189A (ko) 2007-09-11 2010-06-15 유니버시티 오브 매사추세츠 암을 치료하기 위한 인슐린­유사 성장 인자 결합 단백질 7
BRPI0906573A2 (pt) * 2008-01-31 2015-07-07 Univ Keio Método para determinação da sensibilidade para agentes anticâncer
US8093000B2 (en) * 2008-05-09 2012-01-10 The Regents Of The University Of California Methods for predicting and treating tumors resistant to drug, immunotherapy, and radiation
WO2010135786A1 (en) * 2009-05-29 2010-12-02 Clinical Genomics Pty. Ltd. A method for diagnosing neoplasms and molecules for use therein
CA2767621A1 (en) * 2009-07-09 2011-01-13 Abraxis Bioscience, Llc Sparc antisense compositions and uses thereof
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
US20120245089A1 (en) * 2009-09-18 2012-09-27 Abraxis Bioscience, Llc Use of the sparc microenvironment signature in the treatment of cancer
EP3081941B1 (en) * 2009-10-30 2018-06-27 Keio University Method for determination of sensitivity to anti-cancer agent
WO2011135459A2 (en) 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
EP3858385B1 (en) 2010-05-25 2024-09-11 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
MX2012013874A (es) 2010-06-03 2013-01-24 Abraxis Bioscience Llc Uso de la signatura en el microentorno de sparc en el tratamiento de cancer.
WO2012110425A1 (en) * 2011-02-14 2012-08-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for monitoring the response to treatment and for treating colorectal cancer
EA201691257A1 (ru) 2011-06-02 2017-02-28 Олмак Дайэгностикс Лимитед Молекулярно-диагностический тест на рак
US9409978B2 (en) * 2011-09-09 2016-08-09 University Of Massachusetts Modulation of midbody derivatives
HK1214633A1 (zh) 2012-12-03 2016-07-29 Almac Diagnostics Limited 癌症的分子诊断测试
MX371095B (es) 2013-04-10 2020-01-16 Syndevrx Inc Inhibidores de metionina aminopeptidasa-2 y metodos de tratamiento de la obesidad.
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
CN103893763B (zh) * 2014-04-10 2016-05-11 武汉大学 Vinexin-β基因在心肌梗死中的应用
CA2955914C (en) * 2014-07-21 2022-09-06 Ignacio Canals Almazan Tungsten (vi) salts for use thereof in the treatment of infertility, for favoring normal reproduction and fertility in a non-diabetic female mammal, as well as for improving the efficacy of assisted reproductive techniques
US10570457B2 (en) 2014-09-26 2020-02-25 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
CN108290853B (zh) 2015-12-10 2022-05-31 辛德弗雷克斯公司 烟曲霉醇衍生物及其多晶型物
CA3008960C (en) 2016-01-11 2024-07-02 Syndevrx, Inc. TREATMENT OF TUMORS INDUCED BY METABOLIC DYSFUNCTION
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
EP3714896A4 (en) * 2017-11-21 2021-08-04 Miwa, Naofumi HUMAN CANCER CELL METASTASIS INHIBITOR AND HUMAN CANCER CELL DETERMINATION AGENT
CN113196055B (zh) 2018-10-15 2025-06-27 马克斯·普朗克科学促进协会 用于治疗疾病的化合物及其筛选方法
EP3870231A1 (en) 2018-10-26 2021-09-01 Syndevrx, Inc. Biomarkers of metap2 inhibitors and applications thereof
WO2020163795A1 (en) 2019-02-08 2020-08-13 Dewpoint Therapeutics, Inc. Methods of characterizing condensate-associated characteristics of compounds and uses thereof
AU2020274530A1 (en) * 2019-05-15 2021-12-16 Whitehead Institute For Biomedical Research Methods of characterizing and utilizing agent-condensate interactions
CN110331203B (zh) * 2019-07-30 2023-04-18 中南大学湘雅三医院 泛素连接酶chaf1b作为靶位点在制备肺腺癌顺铂增敏药物中的应用
CN114729941A (zh) 2019-09-18 2022-07-08 露点治疗公司 筛选凝聚物相关特异性的方法及其用途
EP4329778A4 (en) * 2021-04-26 2025-02-19 Crititech, Inc. CISPLATIN PARTICLES AND THEIR USES
US20250304625A1 (en) * 2022-04-06 2025-10-02 Vanderbilt University Articles and methods for inhibiting methionine aminopeptidase activity
WO2025057928A1 (ja) * 2023-09-11 2025-03-20 国立大学法人大阪大学 細胞外小胞内ｒｎａ修飾による卵巣癌プラチナ製剤抵抗性を判別するための検査方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
CA2140343A1 (en) 1992-07-17 1994-02-03 Sean M. Sullivan Method and reagent for treatment of animal diseases
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5902880A (en) 1994-08-19 1999-05-11 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US6146886A (en) 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
CA2207593A1 (en) 1994-12-13 1996-06-20 John Gustofson Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
JP2001510808A (ja) 1997-07-24 2001-08-07 イネックス ファーマシューティカルズ コーポレイション 核酸触媒の供給のためのリポソーム組成物
AR013269A1 (es) 1997-08-04 2000-12-13 Scras Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
WO1999031262A2 (en) 1997-12-16 1999-06-24 Valentis, Inc. Needle-free injection of formulated nucleic acid molecules
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6680175B2 (en) * 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
ATE408699T1 (de) 1999-03-10 2008-10-15 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
AU7058000A (en) * 1999-08-13 2001-03-13 Human Genome Sciences, Inc. 13 human colon and colon cancer associated proteins
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20020051978A1 (en) * 2000-02-17 2002-05-02 Roth Frederick P. Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU2001253140A1 (en) * 2000-04-03 2001-10-15 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Tumor markers in ovarian cancer
CA2418320A1 (en) * 2000-08-11 2002-02-21 City Of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
EP1330652B1 (en) * 2000-10-27 2007-06-27 Mount Sinai Hospital Method for detecting ovarian cancer based on human kallikrein 6 (hk6)
US20020182619A1 (en) * 2000-11-08 2002-12-05 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US7195868B2 (en) * 2001-04-18 2007-03-27 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention, and therapy of human cancers
AU2000280389A1 (en) 2001-11-02 2003-05-19 Dana-Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective dna repair mechanisms and treatment thereof
WO2003045323A2 (en) * 2001-11-28 2003-06-05 Mediomics, Llc Anti-angiogenesis methods, compositions and uses therefor
AU2003225851A1 (en) * 2002-03-15 2003-09-29 The Texas A&M University System Strong gene sets for glioma classification
US20040097452A1 (en) * 2002-11-19 2004-05-20 Isis Pharmaceuticals Inc. Modulation of kallikrein 6 expression
JP4682152B2 (ja) * 2003-12-31 2011-05-11 ザ・ペン・ステート・リサーチ・ファンデーション 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法
WO2006044017A2 (en) * 2004-08-13 2006-04-27 Jaguar Bioscience Inc. Systems and methods for identifying diagnostic indicators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOLER E J.Analysis of molecular profile data using generative anddiscriminative methods.PHYSIOLOGICAL GENOMICS4.2001,4109-126. *

Also Published As

Publication number Publication date
WO2005066371A3 (en) 2006-04-20
US20100221731A1 (en) 2010-09-02
US20100221730A1 (en) 2010-09-02
US20160348180A1 (en) 2016-12-01
US20050176669A1 (en) 2005-08-11
JP2007517058A (ja) 2007-06-28
US7700280B2 (en) 2010-04-20
CN102321584A (zh) 2012-01-18
CN102989009A (zh) 2013-03-27
US8192935B2 (en) 2012-06-05
US20100221729A1 (en) 2010-09-02
JP5789591B2 (ja) 2015-10-07
JP5285012B2 (ja) 2013-09-11
JP4682152B2 (ja) 2011-05-11
CN102989009B (zh) 2015-06-03
JP2013079261A (ja) 2013-05-02
EP1704250B1 (en) 2012-09-19
WO2005066371A2 (en) 2005-07-21
EP1704250A2 (en) 2006-09-27
JP2010209076A (ja) 2010-09-24
ES2394799T3 (es) 2013-02-05
TWI301066B (en) 2008-09-21
CN1922332A (zh) 2007-02-28
EP2395112B1 (en) 2017-02-15
EP2395112A1 (en) 2011-12-14
CN102321584B (zh) 2014-01-08
TW200531682A (en) 2005-10-01

Similar Documents

Publication Publication Date Title
CN1922332B (zh) 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
JP5770472B2 (ja) ヒト急性白血病におけるｅｐｈａ７及びｅｒｋリン酸化の調節解除を誘発するための方法及び組成物
JP2012500389A (ja) 多発性脊髄腫の診断、予後および治療のためのマイクロｒｎａに基づく組成物および方法
US20090162361A1 (en) Method for diagnosing pancreatic cancer
JP5764822B2 (ja) がんの治療および診断の標的遺伝子としてのｐｒｍｔ１
CN108753969B (zh) 长链非编码rna在肝细胞癌诊疗中的应用
US20120225076A1 (en) Fra-1 target genes as drug targets for treating cancer
CN108707672B (zh) Duxap8在肝细胞癌诊断和治疗中的应用
CN108624689B (zh) 生物标志物linc01451的应用
KR101808658B1 (ko) 암 진단 키트 및 암 예방 또는 치료용 약제학적 조성물
WO2008069621A1 (en) Novel use of mig12 and oip5 genes
WO2024062445A1 (en) Treatment and method for predicting disease incidence, progression, and prognosis of glioma
KR101115443B1 (ko) 대장암 진단용 조성물 및 그 용도
KR101115446B1 (ko) 대장암 진단용 조성물 및 그 용도
WO2011089197A1 (en) Low levels of cytidine deaminase as a marker for predisposition to develop cancer
WO2010067307A2 (en) In vitro methods and compositions for the diagnosis and/or treatment of adenocarcinoma
WO2008018625A2 (en) Prostate cancer related gene styk1
CN110951888A (zh) 检测及靶向al845472.2的试剂及其在肺癌诊治中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130612

Termination date: 20201230

CF01 Termination of patent right due to non-payment of annual fee